N-methyl-O-(2-pyridyl)-2-aminoethanol | 29450-04-2

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: N-methyl-O-(2-pyridyl)-2-aminoethanol
• 英文别名: 2-(2-Methylaminoethoxy)-pyridin；Methyl[2-(pyridin-2-yloxy)ethyl]amine；N-methyl-2-pyridin-2-yloxyethanamine
• CAS: 29450-04-2
• 化学式: C₈H₁₂N₂O
• 分子量: 152.196
• InChiKey: SWMCABCRDRFOJP-UHFFFAOYSA-N

物化性质

• 沸点：
  238.6±20.0 °C(Predicted)
• 密度：
  1.024±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1
• 重原子数：
  11
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.38
• 拓扑面积：
  34.2
• 氢给体数：
  1
• 氢受体数：
  3

安全信息

• 海关编码：
  2933399090

反应信息

• 作为反应物：
  描述：

  N-methyl-O-(2-pyridyl)-2-aminoethanol 在 sodium cyanoborohydride 作用下， 生成 Anthracen-9-ylmethyl-methyl-[2-(pyridin-2-yloxy)-ethyl]-amine
  参考文献：
  名称：

  Direct visual indication of pH windows: ‘off–on–off’ fluorescent PET (photoinduced electron transfer) sensors/switches

  摘要：

  1-3, which contain a fluorophore and two proton receptors with opposite PET (photoinduced electron transfer) characteristics, only display strong fluorescence within a pH window whose position and width are tunable.

  DOI：

  10.1039/cc9960002399
• 作为产物：
  描述：

  2-氯吡啶 在 palladium on activated charcoal 氢气 、 sodium hydride 作用下， 以 四氢呋喃 、 甲醇 为溶剂， 25.0 ℃ 、344.74 kPa 条件下， 反应 50.0h， 生成 N-methyl-O-(2-pyridyl)-2-aminoethanol
  参考文献：
  名称：

  Synthesis and binding of 6,7,8,9-tetrahydro-5H-pyrido[3,4-d]azepine and related ring-opened analogs at central nicotinic receptors

  摘要：

  6,7,8,9-Tetrahydro-5H-pyrido[3,4-d]azepine (5a) and its N-7-methyl derivative 5b were synthesized and evaluated as potential nicotinic acetylcholinergic receptor (nAChR) ligands. On the basis that 6,7,8,9-tetrahydro-5H-pyrido[3,4-c]azepine (4a), which binds at nAChRs with low affinity (K-i = 1100 nM), possesses an internitrogen distance (4.6 Angstrom) that may be less than optimal, we designed compound 5a due to its similar shape but longer internitrogen distance (5.5 Angstrom). Compound 5a (K-i = 45 nM) was found to bind with enhanced affinity. However, unlike what is seen with nornicotine/nicotine, N-methylation of 5a reduced affinity (5b; K-i = 268 nM) rather than enhancing it. The results suggest that 5 may interact at nicotine receptors in a manner that is somewhat different from that of nicotine. Ring-opening of the pyrido[3,4-d]azepine ring led to a series of 3-(2-aminoethyl)pyridines 21 that retained the affinity of the cyclic compound. Subsequent modification, including further chain lengthening (e.g. aminopropylpyridines 22) and introduction of unsaturation, ultimately led to the development of a series of 3-(2-aminethoxy)pyridines 27. Simple N-substituted derivatives of 27 were found to bind with K-i values of 20 to 35 nM. Because parallel structural changes in several series of related compounds did not result in parallel shifts in nAChR affinity, it is unlikely that all the investigated compounds bind in a similar fashion at these receptors. Nevertheless, some of these compounds represent novel classes of nAChR ligands. (C) Elsevier, Paris.

  DOI：

  10.1016/s0223-5234(99)80051-8

文献信息

• FUSED HETEROCYCLIC COMPOUNDS AS ION CHANNEL MODULATORS
  申请人：Gilead Sciences, Inc.

  公开号：EP3275870A1

  公开（公告）日：2018-01-31

  The present disclosure relates to compounds that are sodium channel inhibitors and to their use in the treatment of various disease states, including cardiovascular diseases and diabetes. In particular embodiments, the structure of the compounds is given by Formula I: wherein Q, R1, X1, X2, Y and R2 are as described herein, to methods for the preparation and use of the compounds and to pharmaceutical compositions containing the same.

  本公开涉及作为钠通道抑制剂的化合物及其在治疗包括心血管疾病和糖尿病在内的各种疾病状态中的用途。在特定的实施方案中，化合物的结构如式 I 所示： 其中Q、R1、X1、X2、Y和R2如本文所述，涉及化合物的制备和使用方法以及含有这些化合物的药物组合物。
• AQUEOUS COATING COMPOSITION COMPRISING PYRIDINE GROUP-CONTAINING ELECTROCOAT RESIN
  申请人：BASF Coatings GmbH

  公开号：EP2382274B1

  公开（公告）日：2015-04-22
• PYRIDINE GROUP-CONTAINING ELECTROCOAT RESIN
  申请人：BASF Coatings GmbH

  公开号：EP2382274A1

  公开（公告）日：2011-11-02
• Novel Substituted Pyrazinone Derivatives for Use in Mch-1 Mediated Diseases
  申请人：Andres-Gil Jose Ignacio

  公开号：US20090012062A1

  公开（公告）日：2009-01-08

  The present invention concerns aryl and heteroaryl substituted pyrazinone derivatives having antagonistic melanin-concentrating hormone (MCH) activity, in particular MCH-1 activity according to the general Formula (I) a pharmaceutically acceptable acid or base addition salt thereof, a stereochemically isomeric form thereof, an N-oxide form thereof or a quaternary ammonium salt thereof, wherein the variables are defined in Claim 1 . It further relates to their preparation, compositions comprising them and their use as a medicine. The compounds according to the invention are useful for the prevention and/or treatment of psychiatric disorders, including but not limited to anxiety, eating disorders, mood disorders, such as bipolar disorders and depression, psychoses, such as schizophrenia, and sleeping disorders; obesity; diabetes; sexual disorders and neurological disorders.
• PYRIDINE GROUP-CONTAINING ELECTROCOAT COMPOSITION WITH METAL OXIDE
  申请人：Chouai Abdellatif

  公开号：US20100167071A1

  公开（公告）日：2010-07-01

  A coating layer prepared from an aqueous electrodeposition coating composition comprising an electrodepositable binder, the binder comprising a aromatic amine group-containing resin, and a metal oxide selected from the group consisting of bismuth oxide, vanadium oxide, manganese oxide, cobalt oxide, zinc oxide, strontium oxide, yttrium oxide, molybdenum oxide, zirconium oxide, lanthanum oxide, oxides of the lanthanide series of elements and combinations of these provides corrosion protection to a metallic substrate.